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Nerve Growth Factor Gene Therapy Using
Adeno-Associated Viral Vectors Prevents Cardiomyopathy
in Type 1 Diabetic Mice
Marco Meloni,1 Betty Descamps,1 Andrea Caporali,1 Lorena Zentilin,2 Ilaria Floris,1 Mauro Giacca,2
and Costanza Emanueli1
Diabetes is a cause of cardiac dysfunction, reduced myocardial
perfusion, and ultimately heart failure. Nerve growth factor (NGF)
exerts protective effects on the cardiovascular system. This study
investigated whether NGF gene transfer can prevent diabetic car-
diomyopathy in mice. We worked with mice with streptozotocin-
induced type 1 diabetes and with nondiabetic control mice. After
having established that diabetes reduces cardiac NGF mRNA ex-
pression, we tested NGF gene therapies with adeno-associated
viral vectors (AAVs) for the capacity to protect the diabetic mouse
heart. To this aim, after 2 weeks of diabetes, cardiac expression
of human NGF or b-Gal (control) genes was induced by either
intramyocardial injection of AAV serotype 2 (AAV2) or systemic
delivery of AAV serotype 9 (AAV9). Nondiabetic mice were given
AAV2–b-Gal or AAV9–b-Gal. We found that the diabetic mice re-
ceiving NGF gene transfer via either AAV2 or AAV9 were spared
the progressive deterioration of cardiac function and left ventric-
ular chamber dilatation observed in b-Gal–injected diabetic mice.
Moreover, they were additionally protected from myocardial
microvascular rarefaction, hypoperfusion, increased deposition
of interstitial ﬁbrosis, and increased apoptosis of endothelial
cells and cardiomyocytes, which afﬂicted the b-Gal–injected dia-
betic control mice. Our data suggest therapeutic potential of NGF
for the prevention of cardiomyopathy in diabetic subjects.Diabetes
61:229–240, 2012
Diabetes is often associated with a speciﬁccardiomyopathy characterized by alterationsin systolic and diastolic function as well asmicroangiopathy. In addition, the diabetic heart
suffers the deposition of interstitial ﬁbrosis, which acts as
a barrier to myocardial perfusion. The overall result is the
development of heart failure during diabetes (1–3).
The neurotrophin nerve growth factor (NGF) is a se-
creted protein, which binds to its high-afﬁnity tropomyosin-
related kinase-A receptor (TrkA). TrkA is expressed on the
plasma membrane of neural and nonneural cells, including
cardiomyocytes and endothelial cells (4–6). In fact, NGF,
via TrkA, is capable of promoting prosurvival effects in
both cardiomyocytes and endothelial cells and promotes
angiogenesis (4,5,7). Using a mouse model of myocardial
infarction induced by coronary artery ligation, we recently
demonstrated that adenovirus-mediated intramyocardial
NGF gene transfer reduces apoptosis of endothelial cells
and cardiomyocytes, improves reparative neovasculariza-
tion, and supports cardiac perfusion (5).
It has been suggested that diabetes alters cardiac NGF
expression (8–10). In particular, Ieda et al. (9) described de-
creased cardiac NGF level after 16 weeks of streptozotocin-
induced diabetes in rats, with associated loss of sensory
nerve ﬁbers and sensory neuropathy. These effects were
also present in diabetic wild-type mice, but NGF transgenic
mice were spared from diabetes-induced sensory neu-
ropathy (9). Importantly, cardiac NGF gene transfer using
a hemagglutinating virus of Japan vector rescued diabetes-
induced sensory denervation in diabetic rats (9). Moreover,
Kaye et al. (11) found reduced cardiac NGF associated with
alterations in sympathetic neuronal function and neuro-
anatomy in nondiabetic rats and humans with congestive
heart failure.
To the best of our knowledge, the possibility that car-
diac NGF gene transfer could prevent diabetes-induced
cardiomyopathy has not previously been evaluated. There-
fore, we investigated whether increasing the myocardial
level of NGF by using adeno-associated viral (AAV) vec-
tors could spare the diabetic heart from failure.
AAVs are small nonenveloped, single-stranded DNA
viruses that can potentially infect all cell types and may
integrate in the genome of the host cell, making it possi-
ble to achieve a long-term transgene expression. Thus far,
several AAV serotypes have been identiﬁed (12,13). All
serotypes share some sequence homology but can have
different tissue tropism and receptor-binding character-
istics. AAV serotype 2 (AAV2) has been widely used be-
cause it possesses a broad tissue tropism. However,
biodistribution studies have shown that AAV2 has low efﬁ-
ciency of cardiac transduction after systemic injection (14).
Conversely, AAV serotype 9 (AAV9) has been shown to
have a preferable muscular transduction after systemic
administration (15), making it ideal for noninvasive thera-
peutic gene transfer of the heart. In the current study, we
compared the effect of cardiac NGF overexpression by two
different strategies: local intramyocardial injection of an
AAV2 vector and systemic AAV9 delivery. We found that
NGF gene transfer via either approach was able to protect
the diabetic heart.
RESEARCH DESIGN AND METHODS
Production, puriﬁcation, and characterization of AAV vectors. Infectious
recombinant AAV particles were generated in human embryonic kidney 293
cells by a cross-packaging approach (16,17) whereby the vector genome was
packaged into AAV capsid serotype 2 (18) or capsid serotype 9 (19,20). Viral
stocks were obtained by CsCl2 gradient centrifugation. For AAV–human NGF
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(hNGF) preparation, the complete coding sequence of hNGF was excised
from a pCMV-hNGF plasmid (LGC Promochem, Teddington, U.K.) and sub-
cloned in the shuttle vector pAAV-MCS (Agilent Technologies, Edinburgh, U.K.).
The plasmids containing the AAV backbones were obtained from Agilent. AAV2-
hNGF and AAV9-hNGF contain a cytomegalovirus promoter, a b-globin intron,
and a human growth hormone polyA signal. AAV–b-Gal drives the expression of
b-galactosidase from a cytomegalovirus promoter and contains an intron from
human growth hormone and a polyA signal derived from SV40.
Animals. In vivo experiments were performed in accordance with the Guide
for the Care and Use of Laboratory Animals (Institute of Laboratory Animal
Resources) and covered by U.K. Home Ofﬁce licenses. Type 1 diabetes was
induced in 8-week-old male CD1 mice (30–33 g body wt; Harlan, Blackthorn,
U.K.) by ﬁve consecutive daily intraperitoneal injections of streptozotocin
(40 mg/kg/day in 0.1 mol/l sodium citrate buffer, pH 4.5; Sigma, Dorset, U.K.)
(21). Age- and sex-matched nondiabetic control mice were injected with the
streptozotocin buffer. Diabetes was conﬁrmed 14 days after the ﬁrst strepto-
zotocin injection by measurement of glycosuria using Test strips (Clinistix;
Bayer, Basel, Switzerland) and reassessed at the moment the mice were killed.
Fasting blood glucose levels were additionally measured at 4, 8, and 12 weeks
in AAV9-injected mice by using a blood glucose meter (Accu-Check; Roche
Diagnostics, Mannheim, Germany). Survival of mice was monitored for the
entire duration of the experiments.
In vivo delivery of AAV vectors. Gene transfer of hNGF or b-Gal control
was performed in diabetic mice 14 days after the ﬁrst streptozotocin injection.
AAV2-hNGF or AAV2–b-Gal was delivered into the left ventricle wall by four
injections (total dose of 1 3 1011 viral particles in 20 mL) (5). AAV9-hNGF and
AAV9–b-Gal were injected in the tail vein (total dose of 1.5 3 1012 viral par-
ticles in 100 mL). Age-matched nondiabetic mice were injected with either
AAV2–b-Gal or AAV9–b-Gal and used for reference.
Efﬁciency of cardiac transduction and biodistribution of AAV vectors.
Efﬁciency of cardiac transduction at 2 and 12 weeks after AAV2–b-Gal intra-
myocardial injection was evaluated by X-Gal staining. Moreover, the presence
of AAV2-hNGF genome was determined by PCR on total DNA isolated from
hearts at 2 weeks post–gene transfer. AAV9-hNGF–mediated efﬁciency and
duration of transduction in the left ventricle were evaluated by real-time RT-PCR
at 2, 4, 8, and 12 weeks post–gene transfer. hNGF biodistribution was addi-
tionally determined at 12 weeks post–gene transfer by real-time RT-PCR in the
right ventricle, liver, kidney, spleen, and adductor muscles. hNGF cDNA level
was normalized to ribosomal protein L32 cDNA level. PCR primers are shown in
Supplementary Table 1. In addition, transgenic NGF protein levels were mea-
sured by ELISA (Promega, Southampton, U.K.) in mouse plasma at 2 and 12
weeks after gene transfer with either AAV2 or AAV9 and in protein extracts of
left ventricle, right ventricle, liver, kidney, spleen, and adductor muscles taken
at 12 weeks from AAV9 injections.
Additional expressional analyses of the myocardium. Murine NGF mRNA
levels were evaluated by real-time RT-PCR in the left ventricle of streptozotocin-
injected diabetic mice (12 weeks) and nondiabetic controls. PCR primers
are shown in Supplementary Table 1, available in the Supplementary Data.
Western blot analyses of left ventricle for total and phospho(Ser473)–Akt-B, total
and phospho(Thr32)-Foxo3a, and tubulin (all from Cell Signaling, Danvers, MA)
were performed at 12 weeks post–gene transfer.
Measurement of cardiac dimensions and function. A high-resolution
echocardiography system (Vevo 770; Visual Sonics, Toronto, Canada) was
used in anesthetized (880 mmol/kg i.p. tribromoethanol; Sigma) mice to measure
the following parameters before gene transfer (baseline) and at 4, 8, and 12
weeks thereafter: heart rate (bpm), left ventricle ejection fraction (LVEF)
(measured as percent), left ventricle fractional shortening (LVFS) (percent),
left ventricle chamber volume (microliters), and left ventricle internal diameter
(LVID) (millimeters) during both systole and diastole (5). Additionally, peak
systolic left ventricle pressure (LVP) (millimeters of Hg), maximal rate of LVP
rise (dP/dtmax) (millimeters of Hg per second), and minimal rate of LVP fall
(dP/dtmin) (millimeters of Hg per second) were measured with a miniaturized
1.4F Millar tip catheter (Millar Instruments, Houston, TX) at 12 weeks post–
gene transfer (5). Moreover, in mice treated with AAV9 vectors, the early-to-
atrial velocity ratio (E-to-A ratio) (index of diastolic function) was measured
by echocardiography and pulsed Doppler at the level of the mitral valve (22).
Measurement of cardiac perfusion. Absolute myocardial blood ﬂow (mil-
limeters per minute per gram of tissue) was determined at 12 weeks post–gene
transfer using ﬂuorescent microspheres (Invitrogen, Paisley, U.K.) as pre-
viously described (5,22). Brieﬂy, anesthetized mice (Tribromoethanol) were
intubated, and a polyethylene catheter (PE10) was inserted into the right ca-
rotid artery and connected to a syringe pump for collection of reference blood.
Then, the chest was opened and microspheres (0.02 mm in diameter) were
injected into the left ventricle cavity (200 ml of total volume). Reference blood
was collected at a rate of 0.15 mL/min. Mice were killed 2 min later, the heart
was removed, and the left ventricle was separated, weighed, cut in small
pieces, and digested in 10 mL of 2M ethanolic KOH (Sigma) at 60°C for 48 h.
Finally, microspheres were collected and ﬂuorescence intensity was deter-
mined by a ﬂuorometer.
Histological analyses. At 12 weeks post–gene transfer, hearts were arrested
in diastole and perfusion ﬁxed for parafﬁn embedding. Capillary and arteriole
densities were evaluated in left ventricle transverse sections (203 magniﬁ-
cation) after staining with isolectin-B4 (endothelial cell marker, 1:100; Invi-
trogen) and for a-smooth muscle actin (for marking vascular smooth muscle
cells, 1:400; Sigma) (5). Apoptosis was determined by transferase-mediated
dUTP nick-end labeling (TUNEL) assay (403 magniﬁcation) (in situ cell death
detection kit Fluorescein; Roche, Indianapolis, IN) (5). TUNEL-positive apo-
ptotic nuclei of endothelial cells were identiﬁed on the basis of cell mor-
phology and vascular localization, while cardiomyocytes were considered
apoptotic when TUNEL-positive stained nuclei were inside the cardiomyocyte
contour. Fibrosis was evaluated using Picrosirius Red staining and revealed by
using a polarized light (203 magniﬁcation). For each staining, ﬁfteen left
ventricle ﬁelds were randomly examined and averaged. Inﬁltrating hemato-
poietic cells were evaluated (203 magniﬁcation) after CD45 (BD Bioscience)
staining developed using 3,39-diaminobenzidine (Dako) followed by Mayer’s
hematoxylin to counterstain the nuclei.
Statistical analyses. All data are expressed as means 6 SEM. ANOVA
was used, followed, when appropriate, by unpaired t test. Survival curves were
analyzed by log-rank test. Analyses were performed using the SigmaStat 3.1
software. A P value ,0.05 was interpreted to denote statistical signiﬁcance.
RESULTS
Myocardial NGF levels decrease in the diabetic mouse
heart. Glycosuria (data not shown) and fasting glycemia
(measured only in the AAV9 protocol [Supplementary
Table 2]) increased in diabetic mice and were not af-
fected by hNGF gene transfer. Relative mRNA expression
of murine NGF decreased by 7.1-fold in the left ventricle
of mice with 12 weeks of diabetes (P, 0.01 vs. age-matched
nondiabetic controls [Supplementary Fig. 1]).
Transgene expression after AAV gene transfer. X-Gal
staining of whole hearts injected 2 and 12 weeks in ad-
vance with AAV2–b-Gal conﬁrmed successful transduc-
tion (Supplementary Fig. 2A–D). Additionally, hNGF DNA
(Supplementary Fig. 2E) and hNGF mRNA (Supplemen-
tary Fig. 2G) were found in hearts that had received AAV2-
hNGF. hNGF protein was present in the mouse plasma at
2 and 12 weeks after either AAV2-hNGF (Supplementary
Fig. 2F) or AAV9-hNGF (Supplementary Fig. 3D). hNGF
plasma levels were similar in the two groups at 2 weeks
(P = not signiﬁcant) but higher in AAV9-injected mice at 12
weeks (P , 0.05). Supplementary Fig. 3A shows the pres-
ence of hNGF mRNA in the left ventricle of AAV9-hNGF–
injected mice at different time points. Supplementary Fig.
3B shows the hNGF mRNA tissue biodistribution at 12
weeks from intravenous AAV9-mediated gene transfer.
After AAV9-hNGF, hNGF mRNA expression was higher in
the heart (left and right ventricles), adductor muscles, and
liver but present in all examined tissues. hNGF protein ex-
pression was found in the left and right ventricles, liver, and
adductor muscles (Supplementary Fig. 3C).
NGF gene transfer prevents left ventricle dysfunction
in diabetic mice. A progressive deterioration of cardiac
function was observed in b-Gal–injected diabetic mice
(Tables 1 and 2). In AAV2–b-Gal diabetic mice, LVEF and
LVFS gradually decreased over time (Table 1), with a sig-
niﬁcant reduction at 12 weeks post–gene transfer (P , 0.05
vs. nondiabetic mice for both comparisons). In AAV9–b-Gal
diabetic mice (Table 2), LVEF was already diminished at
8 weeks post–gene transfer. By contrast, AAV-mediated
hNGF gene transfer preserved both LVEF and LVFS (Tables
1 and 2). Ventricular dilatation was evident in diabetic mice
compared with nondiabetic controls at 12 weeks post–gene
transfer, whereas diabetes-associated left ventricle cham-
ber dilatation and increase in LVID were preserved by
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either AAV2-hNGF or AAV9-hNGF (Tables 1 and 2). Heart
rate gradually decreased over the time in diabetic mice but
was preserved by NGF overexpression (Tables 1 and 2).
Figure 1 shows a decrease in E-to-A ratio, indicative of di-
astolic dysfunction, already at 4 weeks post–gene transfer
in AAV9–b-Gal–injected diabetic mice. Importantly, AAV9-
hNGF improved diastolic function (Fig. 1 and Supplemen-
tary Table 3). In addition, NGF overexpression improved
LVP, dP/dtmax, and dP/dtmin in diabetic mice (Fig. 2A–C for
AAV2- and Fig. 2D–F for AAV9-injected mice).
NGF gene transfer preserves the microvasculature
of the diabetic heart and improves myocardial perfu-
sion. Diabetes causes microvascular rarefaction in the
myocardium (23). Indeed, at 12 weeks of diabetes, hearts
injected with either AAV2–b-Gal or AAV9–b-Gal showed
reduced densities of capillaries and small (diameter,50 mm)
arterioles (Fig. 3). Conversely, cardiac microvasculature
was preserved in diabetic hearts overexpressing NGF
(Fig. 3A–C for AAV2- and Fig. 3E and F for AAV9-injected
mice). The preserved microvessel density was associ-
ated with improved cardiac perfusion after hNGF gene
transfer. In fact, at 12 weeks of diabetes the b-Gal–
expressing hearts showed a signiﬁcant reduction of
blood ﬂow in comparison with that shown without di-
abetes. By contrast, both AAV2-hNGF and AAV9-hNGF
improved cardiac perfusion to values similar to those
observed in nondiabetic controls (Fig. 3D and G).
Diabetes is associated with increased apoptosis in the
heart (24). Accordingly, left ventricle sections at 12 weeks
after diabetes induction and either AAV2–b-Gal or AAV9–b-
Gal showed an increased number of TUNEL-positive
apoptotic endothelial cells and cardiomyocytes compared
with that shown in nondiabetic controls (Fig. 4A–F). By
contrast, AAV2-hNGF and AAV9-hNGF reduced apoptosis
of both cardiovascular cell types (Fig. 4A–C and E for
AAV2-treated mice and Fig. 4D and F for AAV9-treated
mice), providing evidence that sustained cardiac NGF
expression improves cardiac cell survival under diabetic
conditions.
NGF gene transfer promotes the activation of the Akt/
Foxo3a pathway in the diabetic heart. The transcription
factor Foxo3a triggers apoptosis and negatively regulates
TABLE 1
Cardiac functional and dimensional parameters measured by echocardiography in mice treated with AAV2 vectors
Nondiabetes AAV2–b-Gal Diabetes AAV2–b-Gal Diabetes AAV2-hNGF
Ejection fraction (%)
Basal 72.12 6 1.9 72.61 6 1.5 71.68 6 1.8
4 weeks 69.12 6 4.3 65.76 6 3.4 66.28 6 2.1
8 weeks 70.03 6 3.6 64.95 6 1.4 70.77 6 1.9
12 weeks 73.05 6 3.1 64.60 6 1.5* 73.33 6 1.5††
Fractional shortening (%) 38.03 6 1.5 40.35 6 0.8 38.49 6 1.7
Basal
4 weeks 38.74 6 2.6 36.72 6 2.1 37.56 6 2.2
8 weeks 38.21 6 2.8 35.68 6 1.1 40.51 6 1.6
12 weeks 42.54 6 2.8 35.26 6 1.1* 42.55 6 1.3††
LVID (mm)
End diastolic
Basal 4.02 6 0.1 3.90 6 0.1 3.92 6 0.2
4 weeks 3.93 6 0.1 4.01 6 0.1 3.99 6 0.1
8 weeks 3.76 6 0.2 4.19 6 0.1 4.10 6 0.1
12 weeks 4.24 6 0.3 4.42 6 0.1 4.08 6 0.1
End systolic
Basal 2.51 6 0.1 2.35 6 0.1 2.42 6 0.2
4 weeks 2.40 6 0.3 2.45 6 0.1 2.43 6 0.2
8 weeks 2.39 6 0.2 2.71 6 0.1* 2.42 6 0.5
12 weeks 2.45 6 0.2 2.86 6 0.1* 2.34 6 0.1††
Chamber volume (mL)
End diastolic
Basal 74.08 6 5.1 71.55 6 1.9 71.69 6 7.3
4 weeks 74.38 6 4.2 77.24 6 4.4 76.22 6 4.9
8 weeks 72.59 6 6.5 79.53 6 3.2 75.70 6 3.8
12 weeks 81.34 6 6.4 89.13 6 4.9 74.04 6 4.4†
End systolic
Basal 22.32 6 2.2 20.11 6 1.1 21.81 6 4.1
4 weeks 22.67 6 4.7 25.34 6 3.2 23.21 6 2.5
8 weeks 23.54 6 4.5 28.61 6 1.9 23.12 6 1.8
12 weeks 22.74 6 4.1 31.66 6 2.2* 19.86 6 1.5††
Heart rate (bpm)
Basal 494.4 6 10.8 480.3 6 10.2 480.5 6 8.9
4 weeks 473.1 6 10.1 438.8 6 9.2* 452.6 6 7.4
8 weeks 461.2 6 15.4 392.2 6 16.1* 434.7 6 8.3†
12 weeks 478.6 6 15.2 387.1 6 15.4* 455.3 6 18.6†
Data are means 6 SEM. Measurement after AAV2-mediated gene transfer of either hNGF or b-Gal. Boldface indicates statistical differences.
*P , 0.05 vs. nondiabetic mice injected with AAV2–b-Gal. †P , 0.05 and ††P , 0.01 vs. diabetic mice injected with AAV2–b-Gal (n = 8–10
mice/group/time point).
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angiogenesis (4,25). It acts downstream of Akt signaling,
and Akt-dependent phosphorylation of Foxo3a leads to its
inactivation and degradation, thus promoting cell survival
(4,26) and angiogenesis (25). We have previously shown
that NGF activates the Akt/Foxo3a pathway in cultured
cardiomyocytes and in the mouse infarcted heart. We
additionally reported that Akt/Foxo3a signaling plays a
functional role in NGF-induced cardiomyocyte survival
and myocardial angiogenesis (4,5). Moreover, the Akt/Foxo
signaling is known to be altered in the diabetic heart (27).
As shown in Fig. 6, phospho-Akt (active form) and phospho-
Foxo3a (inactive form) were signiﬁcantly reduced at 12
weeks of diabetes in mice injected with b-Gal. Importantly,
NGF gene transfer normalized the phosphorylated-to-total
ratio of both Akt and Foxo3a in the diabetic hearts (Fig.
5A–F). These data suggest that the Akt/Foxo3a pathway
may be involved in the regulation of the antiapoptotic and
proangiogenic effects of NGF in the diabetic heart.
NGF gene transfer reduces ﬁbrosis in the diabetic
heart. Cardiac interstitial ﬁbrosis was signiﬁcantly in-
creased in the heart of diabetic control mice—an effect
that was prevented by NGF overexpression (Fig. 6A–C).
These data together with the improved perfusion in the
hNGF-treated heart, decreased apoptosis of endothelial
cells, and preserved cardiac microvasculature support
the idea that NGF gene transfer is able to preserve the
functionality of small vessels in the diabetic heart. Of
note, no gross evidence of interstitial inﬂammation was
observed in any of the investigated groups (Supple-
mentary Fig. 4).
Effect of diabetes and NGF gene transfer on survival
of mice. In the current study, survival of mice monitored
for 12 weeks showed a substantial increased mortality of
both AAV2– and AAV9–b-Gal-injected diabetic mice com-
pared with that in AAV2– and AAV9–b-Gal-injected non-
diabetic mice (Supplementary Fig. 5A and B). AAV2-hNGF
did not reduce diabetes-associated mortality. By contrast,
diabetic mice given AAV9-hNGF did not show higher
mortality than nondiabetic controls. Although hallmarks
of diabetic cardiomyopathy have been observed during
the progression of diabetes, we cannot exclude that non-
cardiac events, including kidney failure and stroke, may
TABLE 2
Cardiac functional and dimensional parameters measured by echocardiography in mice treated with AAV9 vectors
Nondiabetes AAV9–b-Gal Diabetes AAV9–b-Gal Diabetes AAV9-hNGF
Ejection fraction (%)
Basal 73.90 6 0.9 72.22 6 2.2 72.50 6 0.9
4 weeks 75.12 6 1.3 72.64 6 1.1 74.30 6 0.8
8 weeks 72.87 6 2.2 63.83 6 2.6* 67.93 6 1.1
12 weeks 72.86 6 1.6 63.03 6 1.7* 69.44 6 1.2†
Fractional shortening (%)
Basal 41.67 6 1.1 41.62 6 2.0 39.99 6 1.3
4 weeks 40.22 6 1.5 37.90 6 1.4 37.46 6 1.3
8 weeks 38.00 6 2.6 39.28 6 2.1 37.41 6 1.0
12 weeks 41.85 6 1.5 34.19 6 1.2* 38.48 6 1.0†
LVID (mm)
End diastolic
Basal 4.01 6 0.1 4.10 6 0.1 4.09 6 0.1
4 weeks 4.30 6 0.1 4.15 6 0.1 4.13 6 0.1
8 weeks 4.09 6 0.2 4.12 6 0.2 4.04 6 0.1
12 weeks 3.96 6 0.1 4.49 6 0.1* 4.02 6 0.1†
End systolic
Basal 2.38 6 0.1 2.42 6 0.1 2.39 6 0.1
4 weeks 2.67 6 0.2 2.84 6 0.1 2.69 6 0.1
8 weeks 2.53 6 0.2 2.80 6 0.1 2.48 6 0.1
12 weeks 2.32 6 0.1 2.89 6 0.10* 2.54 6 0.1
Chamber volume (mL)
End diastolic
Basal 73.20 6 2.1 74.65 6 2.9 74.72 6 4.3
4 weeks 66.95 6 1.2 72.59 6 4.0 68.14 6 2.2
8 weeks 65.75 6 2.7 76.48 6 6.4 64.87 6 3.7
12 weeks 66.31 6 4.6 87.96 6 5.3** 72.27 6 4.6†
End systolic
Basal 22.36 6 4.8 23.63 6 2.4 23.13 6 2.5
4 weeks 23.19 6 3.1 27.21 6 0.9 25.25 6 0.8
8 weeks 24.71 6 3.1 28.35 6 3.3 22.44 6 1.9
12 weeks 19.85 6 2.3 32.66 6 2.7* 24.13 6 2.5†
Heart rate (bpm)
Basal 501.1 6 40.1 475.0 6 19.7 490.7 6 23.3
4 weeks 500.1 6 23.3 442.6 6 10.4* 467.8 6 10.4
8 weeks 489.1 6 30.8 409.2 6 20.1* 459.4 6 12.2
12 weeks 490.5 6 6.7 397.2 6 11.9** 459.6 6 11.9†
Data are means 6 SEM. Measurement after AAV9-mediated gene transfer of either hNGF or b-Gal. Boldface indicates statistical differences.
*P , 0.05 and **P , 0.01 vs. nondiabetic mice injected with AAV9–b-Gal. †P , 0.05 vs. diabetic mice injected with AAV9–b-Gal (n = 10–12
mice/group/time point).
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have contributed to mortality in the diabetes groups.
This would be in line with the improved survival after
AAV9-hNGF, which determines a wider hNGF biodistri-
bution (Supplementary Figs. 2G and 3B) and higher cir-
culating hNGF level (Supplementary Figs. 2F and 3D) in
comparison with AAV2-hNGF.
DISCUSSION
Diabetes and its several complications are a major pub-
lic health problem (28). Accumulating evidence from epi-
demiological data and animal and clinical studies shows
that the risk of heart failure is considerably increased by
diabetes, and diabetes has been recognized as one of the
major risk factors for the development of heart failure
(28,29). Nonetheless, the pathophysiology of diabetic
cardiomyopathy remains uncertain and novel therapeutic
strategies for its prevention and rescue are needed. Several
experimental mouse models of type 1 and type 2 diabetes
are available, and some, including mice with streptozotocin-
induced type 1 diabetes and type 2 diabetic db/db mice, have
already been shown to develop cardiomyopathy (22,30,31).
Here, we report that AAV-mediated cardiac NGF over-
expression inhibits the development of cardiomyopathy in
mice with streptozotocin-induced type 1 diabetes. NGF,
which was discovered in the nervous system and initially
considered with respect to its neural functions (32), was
later shown to exert prosurvival actions in the cardiovas-
cular system and to promote angiogenesis, including in the
infarcted heart (4,5). Cardiac NGF expression is altered
during various pathological conditions. For example, NGF
protein levels increase in the peri-infarct area of human
FIG. 1. Effect of AAV9-hNGF on diastolic dysfunction after diabetes (Diab). A: Graph shows the net reduction of E-to-A ratio (E/A ratio) pro-
gressively induced by diabetes in mice injected with AAV9–b2Gal. This effect was reduced by AAV9-hNGF. ○, nondiabetes with AAV9–b-Gal; ■,
diabetes with AAV9–b-Gal; ●, diabetes with AAV9-hNGF. B: Representative mitral ﬂow patterns from pulsed Doppler at 12 weeks (w) after di-
abetes induction. Data are expressed as means 6 SEM. **P< 0.01 vs. nondiabetes with AAV9–b-Gal. ††P< 0.01 vs. diabetes with AAV9–b-Gal (n =
10 mice/group/time point).
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and mouse hearts early after coronary occlusion (5,33). By
contrast, myocardial levels of NGF were reported to be
decreased in the setting of diabetes (8,9)—a ﬁnding that
we have conﬁrmed in the current study. Moreover, the
reduction in cardiac NGF was shown to be a major con-
tribution to cardiac diabetic neuropathy, which could be
reverted by NGF overexpression (9).
The aim of this study was to evaluate the effect of NGF
gene transfer on diabetes-induced cardiac dysfunction and
microvascular rarefaction. Since diabetes is a chronic
disease and the levels of cardiac NGF decrease pro-
gressively in the diabetic heart (10), to sustain NGF ex-
pression we chose an AAV-based gene transfer approach.
In fact, AAVs have the ability to transduce nondividing
cells (including cardiomyocytes) in vivo and to achieve
a sustained transgene expression. AAV serotypes have
minor differences in their capsids, which determine their
tropism (12,13). The discrepancies in tissue tropism among
the different serotypes are partly due to different mecha-
nisms of uptake into target cells but also to postentry
mechanisms involving endosome trafﬁcking, nuclear up-
take, and efﬁciency of viral capsid uncoating (34,35). For
example, AAV2 has a broad tropism and infects a wide
range of tissues with good efﬁciency, while AAV9 displays
the impressive feature of being able to pass through the
endothelial cell barrier of blood vessels when injected
systemically, showing substantial levels of transduction in
the heart muscle (15). In the current study, we ﬁrst pro-
vided evidence of the beneﬁcial effects of cardiac-speciﬁc
overexpression of NGF after local intramyocardial in-
jection by using an AAV2. Then, since this method requires
an invasive surgery and is therefore not optimal as a po-
tential therapy in cardiac patients or for the welfare of re-
search animals, we additionally tested the cardiac responses
to intravenous delivery of AAV9-hNGF.
Left ventricle dysfunction is a common feature of the
diabetic heart. Throughout the development of diabetes,
the contractile capacity of the heart progressively reduces
and the heart shows signs of diastolic and systolic alter-
ations. Left ventricle diastolic dysfunction is considered
one of the earliest hallmarks occurring in the setting of
diabetic cardiomyopathy, and it starts before the onset of
systolic dysfunction (36,37). In the current study, cardiac
function was measured by echocardiography and pulsed
FIG. 2. Impact of AAV2-hNGF and AAV9-hNGF on left ventricle (LV) function in diabetes (Diab). Analyses by Millar tip catheter at 12 weeks post–
gene therapy show left ventricle pressure (A), dP/dtmax (B), and dP/dtmin (C) in AAV2-injected mice. Bar graphs show left ventricle pressure (D),
dP/dtmax (E), and dP/dtmin (F) in AAV9-treated mice. Data are expressed as means 6 SEM. The * symbol indicates statistical differences versus
either nondiabetes with AAV2-b-Gal or nondiabetes with AAV9-b-Gal, while the † symbol indicates differences versus diabetes with either AAV2
or AAV9-b-gal. *P < 0.05 and **P < 0.01 vs. either nondiabetes with AAV9–b-Gal or nondiabetes with AAV2-b-Gal; †P < 0.05 and ††P < 0.01 vs.
either diabetes with AAV9–b-Gal or diabetes with AAV2-b-Gal (n = 8 mice for nondiabetes with AAV2–b-Gal [□], n = 10 mice for diabetes with
AAV2–b-Gal [■], diabetes with AAV2-hNGF [⊞], and nondiabetes with AAV9–b-Gal [⊡]; n = 12 mice for diabetes with AAV9–b-Gal [▨] and di-abetes with AAV9-hNGF [▤]).
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Doppler analyses before diabetes induction and then every
4 weeks. Moreover, at the end of the experiment left
ventricle function was additionally measured by left ventricle
catheterization. In our diabetic mice, echocardiography and
pulsed Doppler analyses showed the presence of diastolic
dysfunction at early stages of diabetes, which conﬁrms our
previous ﬁndings (22,30). In fact, b-Gal–injected mice
exhibited a pronounced decrease in the E-to-A ratio (starting
at 4 weeks of diabetes) and of left ventricle dP/dtmin (which
was assessed as a terminal procedure 12 weeks after
FIG. 3. Impact of AAV-mediated NGF gene therapy on cardiac microvasculature and perfusion after diabetes (Diab). A: Representative micro-
photographs showing capillaries (stained by isolectin-B4 [green ﬂuorescence]) and arterioles (stained by both isolectin-B4 and a-smooth muscle
actin [red and indicated with arrows]) in the left ventricle of AAV2-treated mice. Nuclei are depicted in blue (Dapi). Scale bars: 50 mm. 203
magniﬁcation. Bar graphs show the densities of capillaries (B) and arterioles (C) in AAV2-treated mice. D: Bar graph shows the absolute left
ventricle myocardial blood ﬂow analyzed by ﬂuorescent microspheres in AAV2-injected mice. Bar graphs show capillary density (E), arteriole
density (F), and left ventricle blood ﬂow (G) in AAV9-injected mice. Data are expressed as means 6 SEM. *P< 0.05 vs. nondiabetes with AAV2–b-
Gal or nondiabetes with AAV9–b-Gal; †P < 0.05 vs. diabetes with AAV2–b-Gal or diabetes with AAV9–b-Gal. (For histological analyses, n = 5 mice
for each nondiabetes group and n = 6 mice for all other groups; n = 8 mice/group for blood ﬂow measurement). □, nondiabetes with AAV2–b-Gal;
■, diabetes with AAV2–b-Gal; ⊞, diabetes with AAV2-hNGF; ⊡, nondiabetes with AAV9–b-Gal;▨, diabetes with AAV9–b-Gal;▤, diabetes withAAV9-hNGF. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 4. NGF gene therapy reduces apoptosis of endothelial cells (ECs) and cardiomyocytes in the diabetic heart. Representative microphotographs
showing TUNEL-positive apoptotic nuclei (in purple and indicated by arrows) of endothelial cells (A) and of cardiomyocytes (B) in AAV2-injected
mice. Nuclei are stained in blue (Dapi). Scale bars: 20 mm. (403 magniﬁcation). Bar graphs show the percentage of TUNEL-positive apoptotic en-
dothelial cells (AAV2-treated mice [C] and AAV9-injected mice [D]) and cardiomyocytes (AAV2-injected mice [E] and AAV9-injected mice [F]) in the
left ventricle 12 weeks after diabetes induction. Data are expressed as means 6 SEM. **P < 0.01 vs. nondiabetes with AAV2–b-Gal or nondiabetes
with AAV9–b-Gal; †P < 0.05 vs. diabetes with AAV2–b-Gal or diabetes with AAV9–b-Gal (n = 5 mice for each nondiabetes group and n = 6 mice for
all other groups). □, nondiabetes with AAV2–b-Gal; ■, diabetes with AAV2–b-Gal; ⊞, diabetes with AAV2-hNGF; ⊡, nondiabetes with AAV9–b-Gal;
▨, diabetes with AAV9–b-Gal;▤, diabetes with AAV9-hNGF. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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FIG. 5. Effects of NGF gene therapy on the Akt/Foxo3a pathway in the diabetic heart. A: Representative Western blot bands showing the impact
of 12 weeks of diabetes (Diab) and AAV2-mediated hNGF gene transfer on the phosphorylation of Akt and Foxo3a. Bar graphs show the phos-
phorylation/activation of Akt (B) and phosphorylation/inactivation of Foxo3a (C) in AAV2-injected hearts. Representative Western blot bands (D)
and normalization graphs (E and F) in AAV9-injected hearts. Data are expressed as means 6 SEM. *P < 0.05 vs. nondiabetes with AAV2–b-Gal or
nondiabetes with AAV9–b-Gal; †P < 0.05 vs. diabetes with AAV2–b-Gal or diabetes with AAV9–b-Gal (n = 4 mice for each nondiabetes group and
n = 5 mice for all other groups).
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diabetes induction). Indexes of left ventricle systolic dys-
function were evident at 8 weeks (reduced LVEF) and 12
weeks (reduced dP/dtmax, LVEF, and LVFS) after diabetes
induction. Taken together, in line with previous reports
these results support the presence of diabetes-induced
early diastolic dysfunction followed by systolic dysfunction
(30,36). Moreover, the diabetic heart is also characterized
by structural changes and, in particular, by increased
ventricular dilatation. Notably, echocardiography revealed
signiﬁcant increase in LVID as well as left ventricle
chamber volume dilatation in b-Gal–injected diabetic
hearts. Importantly, NGF overexpression in the diabetic
heart prevented left ventricle diastolic and systolic dys-
function and reduced left ventricle chamber dimensions.
These results suggest that lack of NGF is detrimental for
cardiac performances in the diabetic heart at both earlier
FIG. 6. Effect of NGF gene therapy on diabetes (Diab)-induced interstitial ﬁbrosis. A: Representative microphotographs of left ventricle sections
after Picrosirius Red staining. Collagen deposition is revealed in bright yellow via use of a polarized light (203magniﬁcation). Bar graphs show the
amount of interstitial ﬁbrosis after either AAV2-mediated (B) or AAV9-mediated (C) gene therapy. Data are expressed as means 6 SEM. **P <
0.01 vs. nondiabetes with AAV2–b-Gal or nondiabetes with AAV9–b-Gal; †P< 0.05 vs. diabetes with AAV2-b-Gal or diabetes with AAV9-b-Gal (n =
5 mice for each nondiabetes group and n = 6 mice for all other groups). (A high-quality digital representation of this ﬁgure is available in the online
issue.)
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and later stages of cardiomyopahty. On the other hand,
NGF gene transfer appears utilitarian for improving car-
diac function in diabetes. Diabetes is often characterized
by cardiac autonomic neuropathy that results in sympa-
thetic nerve damage and consequent alteration of circu-
lating catecholamine levels and heart rate (38). Given that
NGF regulates cardiac sympathetic innervation (9), it is
possible that NGF overexpression could prevent nerve
damage in the diabetic heart. In line with this, heart rate
was higher in diabetic mice treated with hNGF. We did
not evaluate the effects of NGF overexpression on car-
diac innervations or plasma catecholamines, which rep-
resents a limitation of our study. Microvascular rarefaction
is another common hallmark of the diabetic heart. Diabetic
myocardial microangiopathy has been shown in both
humans and rodents with streptozotocin-induced diabetes
(39,40). Changes in the cardiac microvascular architecture
are causally associated with increased apoptosis of endo-
thelial cells, ﬁbrosis deposition, and reduction of cardiac
perfusion. Immunohistological analyses of heart sections
at 12 weeks of diabetes conﬁrmed a reduced number of
capillaries and small-size arterioles and increased endo-
thelial cell and cardiomyocyte apoptosis, conﬁrming pre-
vious reports in diabetic patients and animals (41,42). The
antiapoptotic and proangiogenic effects of NGF are well
documented in several tissues and in different types of pa-
thologies (4,5,7,43,44). The serine-threonine kinase Akt
plays a crucial role in the prosurvival and proangiogenic
effects of NGF (7,45,46). Phosphorylation/activation of Akt
downstream of the NGF high-afﬁnity receptor TrkA leads
to the phosphorylation/inactivation of the Forkhead
transcription factor Foxo3a, resulting in cardiomyocyte
survival and angiogenesis (4,25). Moreover, Akt-Foxo sig-
naling is altered in the diabetic heart (27). In agreement
with our previous reports demonstrating the involvement
of Akt/Foxo3a signaling in the prosurvival and proangio-
genic effects of NGF (4,5), here we show that NGF over-
expression increases Akt and Foxo3a phosphorylation
in the diabetic heart, which may explain the cardiopro-
tective effects. In the current study, we have found that
AAV-mediated NGF cardiac overexpression preserves the
vascular architecture of the diabetic myocardium. These
signiﬁcant effects of NGF gene transfer were also em-
phasized by increased myocardial perfusion in the presence
of diabetes. Finally, another frequent feature of the diabetic
heart is increased interstitial ﬁbrosis, which results in
increased left ventricle stiffness, thus compromising the
ability of the heart to contract and relax efﬁciently
(47,48). In line with this, histological analyses performed
at 12 weeks of diabetes demonstrated accumulation of
ﬁbrotic content in the interstitial myocardium of b-Gal–
injected diabetic mice, with a signiﬁcant reduction after
NGF gene transfer, indicating that NGF overexpression
confers protection against cardiac ﬁbrosis induced by
diabetes.
At 12 weeks from gene transfer, similar cardiac hNGF
mRNA expression was found in mice treated with AAV2
and AAV9. However, hNGF plasma levels were higher
after AAV9. This is in line with the different tissue bio-
distribution observed in the two gene transfer approaches
and suggests that the heart is not the only source of cir-
culating hNGF after AAV9-hNGF injection. As the two gene
transfer approaches resulted in comparable cardiac ef-
fects, it is possible that the amount of hNGF produced by
AAV2-hNGF was sufﬁcient to ensure optimal cardiac
protection.
In conclusion, our results suggest that NGF gene transfer
might have a tremendous therapeutic potential for the
treatment of diabetic cardiomyopathy and encourage further
translational efforts for the ﬁnal beneﬁt of diabetic patients.
However, before this gene transfer approach can be tested in
patients, additional preclinical studies need to be performed
(including in larger animals) not only to verify the efﬁciency
and the safety of AAV-mediated NGF overexpression in the
setting of type 1 diabetes but also to ﬁnd the most efﬁcient
AAV serotype, as well as the optimal dose and delivery route
to be used. Moreover, since NGF is secreted and TrkA is
present in several cell types, a better understanding of NGF
gene transfer impact on noncardiac tissues and organs needs
to be developed. Moreover, potential side effects common to
all other proangiogenic and prosurvival factors (like tumor
and ocular angiogenesis and inﬂammatory angiogenesis of
joints) should also be considered. Finally, it seems important
to preclinically evaluate the result of NGF gene transfer in
association with insulin and other therapeutic treatments
commonly used in diabetic patients.
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